Summary
Pravastatin sodium (pravastatin) is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, and was found to be highly effective in animals and humans, in lowering the plasma cholesterol level by inhibiting cholesterol synthesis selectively in the liver. In the present study the disposition and metabolism of pravastatin was studied in rats, dogs and monkeys using [14C]-labelled compound. The extent of absorption was approximately 70% in rats and 50% in dogs. Tissue distribution examined by both whole-body autoradiography and radioactivity measurement demonstrated that the drug was selectively taken up by the liver, a target organ of the drug, and excreted via bile mainly in unchanged form. Since pravastatin excreted by the bile was reabsorbed, the enterohepatic circulation maintained the presence of unchanged pravastatin in the target organ. The profiles of metabolites were studied in various tissues and excreta and a metabolic pathway of pravastatin was proposed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tsujita Y., Kuroda M., Shimada Y., et al. (1986): CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase:tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim. Biophys. Acta, 877, 50–60.
Nakaya N., Homma Y., Tamachi H., Goto Y. (1986): The effect of CS-514, an inhibitor of HMG-CoA reductase, on serum lipids in healthy volunteers. Atherosclerosis, 61, 125–128.
Yoshino G., Kazumi T., Iwai M., et al. (1989): Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514). Atherosclerosis, 75, 67–72.
Muramatsu S., Miyaguchi K., Iwabuchi H., et al. (1992): Metabolism of pravastatin sodium in isolated rat hepatocytes (I) Glutachione conjugate formation reaction. Xenobiotica, 22, 487–498.
Nakamura T., Yoda K., Kuwano H., et al. (1991): Metabolism of pravastatin sodium in isolated rat hepatocytes (II) Structure elucidation of the metabolites by N.M.R. spectroscopy. Xenobiotica, 21, 277–293.
Kitazawa E., Iwabuchi H., Uchiyama M., Kitagawa A., Muramatsu S., Kuwano H. (1989): Metabolic study on pravastatin sodium (3) Identification of rat plasma metabolites, 109th Annual meeting of The Pharmaceutical Society of Japan, Nagoya, Japan, Abstract IV, p 2 (in Japanese).
Serizawa N., Nakagawa K., Tsujita Y., Terahara A., Kuwano H. (1983): 3α-hydroxy-ML-236B(3α -hydroxycompactin), microbial transformation product of ML-236B(compactin). J. Antibiot., 36, 608–610.
Serizawa N., Nakagawa K., Tsujita Y., Terahara A., Kuwano H., Tanaka M. (1983): 6α-Hydroxy-iso-ML-236B-(6α-hydroxy-iso-compactin) and ML-236A, microbial transformation products of ML-236B. J. Antibiot., 36, 918–920.
Duggan D.E., Chen I.W., Bayne W.F., et al. (1989): The physiological disposition of lovastatin. Drug Metab. Dispos., 17, 166–173.
Mahoney E.M., Child MJ., Smith-Monroy CA. (1990) : Differential transport of pravastatin and lovastatin by hepatocytes and fibroblasts. Circulation, 82(4), Abstract No. 0023.
Komai T., Shigehara E., Tokui T., et al. (1992): Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem. Pharmacol., 43, 667–670.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Komai, T., Kawai, K., Tokui, T. et al. Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys. Eur. J. Drug Metab. Pharmacokinet. 17, 103–113 (1992). https://doi.org/10.1007/BF03188778
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03188778